Taysha Gene Therapies (TSHA) Shares Outstanding (Weighted Average) (2019 - 2026)

Taysha Gene Therapies has disclosed Shares Outstanding (Weighted Average) across 8 years of filings, most recently posting $366.6 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $366.6 million, up 36.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $366.6 million (up 36.14% YoY), and the FY2025 annual result was $319.7 million, up 27.82% from the prior year.
• Shares Outstanding (Weighted Average) came in at $366.6 million for Q1 2026 at Taysha Gene Therapies, up from $319.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $366.6 million in Q1 2026 to a low of $38.2 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $231.2 million (2024), against an average of $178.6 million.
• Across the five-year window, Shares Outstanding (Weighted Average) grew 3.2% in 2022 and jumped 265.55% in 2024, its largest moves.
• Taysha Gene Therapies' Shares Outstanding (Weighted Average) stood at $44.0 million in 2022, then jumped by 164.2% to $116.1 million in 2023, then surged by 115.41% to $250.1 million in 2024, then increased by 27.82% to $319.7 million in 2025, then grew by 14.68% to $366.6 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $366.6 million (Q1 2026), $319.7 million (Q4 2025), and $307.2 million (Q3 2025), per Business Quant data.